BUDGET IMPACT ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION
Author(s)
Yagudina R, Kulikov A, Serpik V, Kostina E, Protsenko M
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
OBJECTIVES : To conduct budget impact analysis of SMBG devices with different error ranges in diabetes mellitus (DM) patients in the Russian Federation. METHODS : A budget impact model was developed in MS Excel to simulate the costs of SMBG devices for 5 year time horizon. Direct costs included the correction of complications of DM, insulin therapy, SMBG devices, test strips. The cost for completed case of complication treatment: severe hyperglycemia - EUR 336, renal diseases - EUR 813, stroke - EUR 867, myocardial infarction - EUR 514, amputation - EUR 4 372, macular edema - EUR 1 185. Indirect costs included loss of gross domestic product and disability pension. The number of patients with DM are 4 498 955 in the Russian Federation. The exchange rate used EUR 1 = 72 RUB. RESULTS : The budget impact analysis for 5 year time horizon showed that the use of the SMBG device with MRAD 4,85% compared to the SMBG device with MRAD 10,05% requires additional funding for one average patient is EUR 183 per year and is EUR 921 for 5 years. CONCLUSIONS : The results of the budget impact analysis showed that switching patients from the SMBG device with MRAD of 10,05% to the SMBG device with MRAD of 4,85% the treatment of all patients with DM requires additional funding of EUR 829 257 277 per year in the Russian Federation.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PDB22
Topic
Clinical Outcomes, Economic Evaluation, Medical Technologies
Topic Subcategory
Budget Impact Analysis, Clinical Outcomes Assessment, Medical Devices
Disease
Medical Devices
Explore Related HEOR by Topic